IRFI 042

Drug Profile

IRFI 042

Latest Information Update: 25 Oct 2005

Price : $50

At a glance

  • Originator Biomedica Foscama
  • Class Anti-ischaemics; Small molecules
  • Mechanism of Action Antioxidants; Lipid peroxidation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Atherosclerosis; Reperfusion injury

Most Recent Events

  • 25 Oct 2005 IRFI 042 is no longer available for licensing
  • 20 Oct 2005 Discontinued - Preclinical for Atherosclerosis in Italy (PO)
  • 20 Oct 2005 Discontinued - Preclinical for Reperfusion injury in Italy (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top